semaglutide and mcas A newly published case series reports that GLP-1 receptor agonists (like tirzepatide) may significantly improve symptoms in patients with mast cell activation syndrome (MCAS), even in those without diabetes or GLP-1 Genetics: How Genes Affect
Description
Rapid weight loss with GLP1 receptor agonists can come at the cost of skeletal muscle, potentially undermining metabolic and functional outcomes

Get useful tips to avoid gaining weight after stopping Ozempic.
Maintaining weight loss requires continuous treatment, dietary consistency, and exercise

However, while GLP-1 receptor agonists may eventually play a role &mdash

Bifidobacterium infantis promotes microbiome diversity
Conclusion Semaglutide treatment in eligible US adults may substantially reduce obesity prevalence and CVD events, which may dramatically impact associated healthcare costs.